Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Alrosa issued digital financial assets diamonds

3/29/24 ALRS

Acron reports for 2023 by IFRS

3/29/24 AKRN

Rosatom does not plan to make an offer to Fesco minority shareholders

3/29/24 FESH

First stage of Arctic LNG-2 launched

3/29/24 NVTK

Pyatyorochka started operations in Zabaikalsky Krai

3/29/24 X5

YandexGPT learned the Kazakh language

3/29/24 YNDX

Seligdar reports for 2023 by RAS

3/29/24 SELG

SPB Exchange reported for 2023 by RAS

3/29/24 SPBE

Europlan IPO was at the upper end of the price range

3/29/24 LEAS

Whoosh optimizes asset management structure in Latin America

3/29/24 WUSH